Home › Funds › Vestal Point Capital, LP › SLDB

Vestal Point Capital, LP position in SLDB

SOLID BIOSCIENCES INC COM NEW · Health Care

Vestal Point Capital, LP reported holding 2,160,000 shares of SLDB (SOLID BIOSCIENCES INC COM NEW) in its Q2 2026 13F filing — a position valued at US$21.6M, representing 0.50% of its reported portfolio and ranking #42 among its reported holdings. Vestal Point Capital, LP has disclosed SLDB holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.16M sh
Reported value held$21.58M
Portfolio Weight0.50%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's SLDB position evolved

Vestal Point Capital, LP first disclosed a stake in SLDB in Q4 2023 at 34,085 shares (US$209K). The position peaked in Q1 2026 at 5,000,000 shares, worth US$36.0M. Across 11 filings, Vestal Point Capital, LP increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,160,000 shares valued at US$21.6M — a reduction of -2,840,000 shares quarter over quarter.. Notable position changes include a 2937% increase in Q1 2024 (shares fell 57% over the following quarter), a 157% increase in Q2 2024 (shares rose 23% over the following quarter), a 98% increase in Q3 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 34.09K $209.28K New
Q1 2024 1.03M $13.79M Add
Q2 2024 2.67M $15.11M Add
Q3 2024 2.80M $19.52M Add
Q4 2024 2.85M $11.40M Add
Q1 2025 1.75M $6.49M Reduce
Q2 2025 1.50M $7.33M Reduce
Q3 2025 2.98M $18.36M Add
Q4 2025 5.82M $32.80M Add
Q1 2026 5.00M $36.00M Reduce
Q2 2026 2.16M $21.58M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SLDB and 13F data

SLDB (SOLID BIOSCIENCES INC COM NEW) is a Health Care company. 48 other funds we track also report a position in SLDB — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$120.2M), PERCEPTIVE ADVISORS LLC (US$118.9M), Bain Capital Life Sciences Investors, LLC (US$98.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SLDB

All SLDB fund holders →

FAQ

How long has Vestal Point Capital, LP held SLDB?

Vestal Point Capital, LP has disclosed SLDB holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Vestal Point Capital, LP's current position in SLDB?

As of Q2 2026, Vestal Point Capital, LP holds 2.16M shares of SLDB (SOLID BIOSCIENCES INC COM NEW), valued at $21.58M, representing 0.50% of its reported portfolio and ranking #42.

Has Vestal Point Capital, LP been buying or selling SLDB?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in SLDB. The position peaked in Q1 2026 at 5.00M shares.

Which other funds hold SLDB?

Other major institutional holders of SLDB include RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.